3-MMC

Controlled trial documented statistically significant blood pressure elevation at 25–100 mg in healthy volunteers. Individuals with uncontrolled or poorly controlled hypertension face compounded cardiovascular risk.

Individuals with coronary artery disease, prior myocardial infarction, or angina face risk of acute coronary syndrome from sympathomimetic cardiovascular stress.

Pre-existing arrhythmias including atrial fibrillation, supraventricular tachycardia, and ventricular arrhythmias are absolute contraindications due to risk of hemodynamic compromise under additional sympathomimetic load.

Individuals with schizophrenia, schizoaffective disorder, or history of psychotic episodes should avoid 3-MMC. The compound's potent dopaminergic activity directly opposes antipsychotic pharmacology and may trigger relapse.

Individuals with bipolar I or II disorder face risk of mood destabilization, particularly manic switching, from potent catecholamine-releasing agents.

Documented hepatotoxicity at human-relevant concentrations in rat hepatocytes (Dias da Silva et al. 2019). Individuals with pre-existing liver disease, hepatitis, or hepatic enzyme elevation face increased risk of hepatocellular damage.

No safety data in pregnancy. As a potent catecholamine-releasing agent, 3-MMC poses theoretical risk of reduced uteroplacental blood flow, fetal tachycardia, and developmental effects. Absolute contraindication by precautionary principle.

Concurrent use of MAOIs (including moclobemide, phenelzine, tranylcypromine, selegiline) with 3-MMC is absolutely contraindicated. This combination is expected to produce severe, potentially fatal serotonin syndrome and hypertensive crisis.

SSRIs, SNRIs, and other serotonin-active medications increase the risk of serotonin syndrome when combined with 3-MMC. Dual pharmacokinetic interaction via CYP2D6 may further complicate the picture.